



International
Federation of
Pharmaceutical
Manufacturers &
Associations

Fédération
Internationale de
l'Industrie du
Médicament

Federación
Internacional de la
Industria del
Medicamento



News Release

IFPMA Announces Johnson & Johnson as New Member Company

Geneva, 24 June 2009 – The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) is pleased to announce that Johnson & Johnson has become its newest member company.

IFPMA Acting Director General Michael D. Boyd said: “Johnson & Johnson is an important company in our industry and one which is particularly active in working to help improve health in developing countries. The IFPMA is very pleased that Johnson & Johnson has joined; this is good for the IFPMA, and we expect it will benefit Johnson & Johnson, as well.”

Johnson & Johnson is the world's most comprehensive healthcare company, with more than 250 companies in 57 countries employing 119,000 people worldwide engaged in the research and development, manufacture and sales of a broad range of health care products, including pharmaceuticals, medical devices and diagnostics. Its worldwide headquarters is in New Brunswick, New Jersey, USA.

The company is committed to bringing innovative ideas, products and services to market that advance the health and well-being of people throughout the world.

For general information on Johnson & Johnson, please go to www.jnj.com. For information on the company's activities to help improve health in underserved communities, please go to <http://www.jnj.com/connect/caring/medicine-access/>.

(ends)

About the IFPMA:

The International Federation of Pharmaceutical Manufacturers & Associations is the global non-profit NGO representing the research-based pharmaceutical, biotech and vaccine sectors. Its members comprise 27 leading international companies and 44 national and regional industry associations covering developed and developing countries. The industry's R&D pipeline contains hundreds of new medicines and vaccines being developed to address global disease threats, including cancer, heart disease, HIV/AIDS and malaria. The IFPMA Clinical Trials Portal (www.ifpma.org/ClinicalTrials), the IFPMA's Ethical Promotion online resource (www.ifpma.org/EthicalPromotion/) and its Developing World Health Partnerships information (www.ifpma.org/HealthPartnerships) help make the industry's activities more transparent. The IFPMA strengthens patient safety by improving risk assessment of medicines and combating their counterfeiting. It also provides the secretariat for the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH).

For further information, please contact:

Guy Willis
Director of Communications
E-mail: g.willis@ifpma.org
Tel: +41 22 338 32 00
Fax: +41 22 338 32 99
Web: www.ifpma.org